Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
6.85
-9.18 (-57.27%)
At close: May 7, 2026, 4:00 PM EDT
6.84
-0.01 (-0.15%)
After-hours: May 7, 2026, 7:59 PM EDT
Entrada Therapeutics Employees
Entrada Therapeutics had 152 employees as of December 31, 2025. The number of employees decreased by 31 or -16.94% compared to the previous year.
Employees
152
Change (1Y)
-31
Growth (1Y)
-16.94%
Revenue / Employee
$37,750
Profits / Employee
-$1,092,882
Market Cap
250.27M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 152 | -31 | -16.94% |
| Dec 31, 2024 | 183 | 24 | 15.09% |
| Sep 30, 2024 | 177 | 27 | 18.00% |
| Jun 30, 2024 | 168 | 37 | 28.24% |
| Mar 31, 2024 | 160 | 30 | 23.08% |
| Dec 31, 2023 | 159 | 29 | 22.31% |
| Sep 30, 2023 | 150 | 26 | 20.97% |
| Jun 30, 2023 | 131 | 9 | 7.38% |
| Mar 31, 2023 | 130 | 16 | 14.04% |
| Dec 31, 2022 | 130 | 16 | 14.04% |
| Sep 30, 2022 | 124 | 26 | 26.53% |
| Jun 30, 2022 | 122 | 44 | 56.41% |
| Mar 31, 2022 | 114 | 36 | 46.15% |
| Dec 31, 2021 | 114 | - | - |
| Sep 30, 2021 | 98 | - | - |
| Jun 30, 2021 | 78 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| ProKidney | 231 |
| Prime Medicine | 146 |
| Kyverna Therapeutics | 130 |
| Adlai Nortye | 109 |
| enGene Therapeutics | 82 |
| Prothena Corporation | 67 |
| AgomAb Therapeutics NV | 58 |
TRDA News
- 8 hours ago - Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why - Benzinga
- 13 hours ago - Entrada Therapeutics Transcript: Study result - Transcripts
- 15 hours ago - Entrada Therapeutics Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 15 hours ago - Entrada's Duchenne drug shown to improve muscle function in early trial - Reuters
- 15 hours ago - Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study - GlobeNewsWire
- 1 day ago - Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026 - GlobeNewsWire
- 2 months ago - Entrada Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire